3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Classical hematology
1
Conditions
Leukemia, Myeloid, Acute
2
Pathologic Complete Response
1
Lymphoma, T-Cell
1
Lymphoma
1
Anemia, Refractory, with Excess of Blasts
1
Interventions
Cytarabine
9
Daunorubicin
7
Etoposide
6
Methotrexate
5
Idarubicin
5
Thioguanine
4
Mitoxantrone
4
Cyclophosphamide
4
Hydrocortisone
3
Granulocyte Colony-Stimulating Factor
3
Filgrastim
3
Asparaginase
3
Tacrolimus
2
Radiotherapy
2
Peripheral Blood Stem Cell Transplantation
2
ON 01910
2
Mycophenolic Acid
2
Dexamethasone
2
Busulfan
2
zosuquidar trihydrochloride
1
valspodar
1
tipifarnib
1
sargramostim
1
palmitoyl-L-asparaginase
1
merphos
1
lonafarnib
1
hydrocortisone hemisuccinate
1
fludarabine phosphate
1
fludarabine
1
cc-486
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Anemia, Refractory, with Excess of Blasts
×
cc-486
×
Clear all
NCT04173533
2024-05-14
AMADEUS
University of Birmingham
Phase 3
Unknown
326 enrolled